Weight Reducing and Metabolic Effects of Topiramate in Patients with Migraine – an Observational Study

Abstract

Topiramate is an anticonvulsant agent effective in the prophylaxis of migraine, which also induces weight reduction by an unknown mechanism. We investigated the effect of topiramate on metabolic and endocrine parameters in patients with migraine independently of any intention to lose body weight. Six patients (26–61 years old, body mass indices [BMI] 20.9–32.1 kg/m²) with migraine were treated with an average dose of 100 mg topiramate/day over a period of 20 weeks. The following parameters were measured every 4–8 weeks: BMI, body fat proportion, waist and hip circumference, HOMA insulin resistance, fasting serum-/plasma concentrations of adiponectin, leptin, ghrelin, vascular endothelial growth factor (VEGF), cortisol, interleukin-6 and tumor necrosis factor (TNF)-α. Profound metabolic changes were observed for the whole treatment period. Compared with the baseline value, 20 weeks of treatment reduced the BMI by 7.2±1.4%, body fat proportion by 11.6±3.6%, waist circumference by 4.2±1.2%, leptin by 39.2±6.5% and HOMA insulin resistance by 37.3±5%, while adiponectin was increased by 69.9±17.3% (P<0.05, respectively). VEGF concentrations increased during the week 2–4 by 177.4±39.4% (P<0.05) followed by a continuous decrease. There were trends for a reduction in ghrelin concentration, whereas cortisol, interleukin-6 and TNF-α values were unchanged. In summary, in this small sample of migraine patients topiramate treatment was associated with increased insulin sensitivity, increased adiponectin concentration and a reduction of body fat in all treated patients. The role of increased VEGF concentrations prior to these metabolic changes is not clear and might, hypothetically, involve a centrally mediated effect of topiramate on body weight regulation.

topiramate - obesity - VEGF - migraine

References

• 1 Astrup A, Caterson I, Zelissen P. et al . Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.  Obes Res. 2004;  12 1658-1669
• 2 Astrup A, Toubro S. Topiramate: a new potential pharmacological treatment for obesity.  Obes Res. 2004;  12 ((Suppl)) S167-S173
• 3 Biton V, Montouris GD, Ritter F. et al . A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group.  Neurology. 1999;  52 1330-1337
• 4 Bray GA, Hollander P, Klein S. et al . A 6-month randomized, placebo-controlled, dose-ranging trial for weight loss in obesity.  Obes Res. 2003;  11 722-723
• 5 Chengappa KN, Chalasani L, Brar J. et al . Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review.  Clin Ther. 2002;  24 1576-1584
• 6 Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients.  BMJ. 2001;  322 716-720
• 7 Gómez-Ambrosi J, Catalán V, Rodríguez A. et al . Involvement of serum vascular endothelial growth factor family members in the development of obesity in mice and humans.  J Nutr Biochem. 2009;  in press
• 8 Headache classification committee of the HIS . Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.  Cephalalgia. 1988;  8 1-96
• 9 Hubold C, Oltmanns KM, Schultes B. et al . High plasma VEGF relates to low carbohydrate intake in patients with type 2 diabetes.  Int J Obes. 2006;  30 1356-1361
• 10 Oltmanns KM, Melchert UH, Scholand-Engler HG. et al . Divergent effects of hyper- and hypoglycemia on circulating vascular endothelial growth factor in humans.  Metabolism. 2008;  57 90-94
• 11 Peters A, Langemann D. Build-ups in the supply chain of the brain: on the neuroenergetic cause of obesity and type 2 diabetes mellitus.  Front Neuroenergetics. 2009;  1 1-15
• 12 Proescholdt MA, Jacobson S, Tresser N. et al . Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats.  J Neuropathol Exp Neurol. 2002;  61 914-925
• 13 Richard D, Ferland J, Lalonde J Samson P. et al . Influence of topiramate in the regulation of energy balance.  Nutrition. 2000;  16 961-966
• 14 Richard D, Picard F, Lemieux C. et al . The effects of topiramate and sex hormones on energy balance of male and female rats.  Int J Obes Relat Metab Disord. 2002;  26 344-353
• 15 Roy Chengappa KN, Levine J, Rathore D. et al . Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series.  Eur Psychiatry. 2001;  16 186-190
• 16 Schuler-Springorum M, Hebebrand J, Wehmeier PM. et al . Is topiramate effective for weight loss in neuroleptic-induced obesity? 2 case reports.  Z Kinder Jugendpsychiatr Psychother. 2002;  30 51-58
• 17 Shank RP, Gardocki JF, Streeter AJ. et al . An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action.  Epilepsia. 2000;  41 (S 01) S3-S9
• 18 Silberstein SD, Ben-Menachem E, Shank RP. et al . Topiramate monotherapy in epilepsy and migraine prevention.  Clin Ther. 2005;  27 154-165
• 19 Toplak H, Hamann A, Moore R. et al . Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.  Int J Obes. 2007;  31 138-146
• 20 Tremblay A, Chaput JP, Berube-Parent S. et al . The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.  Eur J Clin Pharmacol. 2007;  63 123-134
• 21 Wilding J, Van Gaal L, Rissanen A. et al . OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long term efficacy and safety of topiramate in the treatment of obese subjects.  Int J Obes Relat Metab Disord. 2004;  28 1399-1410
• 22 Yeckel CW, Weiss R, Dziura J. et al . Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents.  J Clin Endocrinol Metab. 2004;  89 1096-1101

1 present address: Department of Neurology and Clinical Neurophysiology, Academic Hospital Bogenhausen, Technical University of Munich, Germany.^*

Correspondence